Some thoughts about today's PR. "We have ample
Post# of 72446
Posted On: 12/14/2015 6:56:31 PM
Some thoughts about today's PR.
"We have ample data, and very compelling data for that matter, to end the trial, but we don’t want to miss any opportunity for expanded research by an exceptional PI (Principal Investigator) team, so we have some important decisions to make."
By not ending the trial, Dana-Farber can continue dosing patients at the highest dosage and collect long-term safety and efficacy data. Some patients must have been getting great benefits and want to continue dosing.
"1. Start of Kevetrin advanced study in ovarian cancer"
Leo didn't say Phase 2. Advanced study could mean Phase 2/3.
"3. Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2)"
The initial results of B-OM must be promising, otherwise Leo wouldn't have mentioned it. Another big hint from Leo IMO.
"We are in early stage discussions regarding Kevetrin’s use in eye diseases in a joint venture (JV) with another company, which has a unique technology for eye cancer treatments."
This is the most exciting part! A partner will bring instant credibility to the company, not to mention some upfront money.
"We have ample data, and very compelling data for that matter, to end the trial, but we don’t want to miss any opportunity for expanded research by an exceptional PI (Principal Investigator) team, so we have some important decisions to make."
By not ending the trial, Dana-Farber can continue dosing patients at the highest dosage and collect long-term safety and efficacy data. Some patients must have been getting great benefits and want to continue dosing.
"1. Start of Kevetrin advanced study in ovarian cancer"
Leo didn't say Phase 2. Advanced study could mean Phase 2/3.
"3. Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2)"
The initial results of B-OM must be promising, otherwise Leo wouldn't have mentioned it. Another big hint from Leo IMO.
"We are in early stage discussions regarding Kevetrin’s use in eye diseases in a joint venture (JV) with another company, which has a unique technology for eye cancer treatments."
This is the most exciting part! A partner will bring instant credibility to the company, not to mention some upfront money.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
